{"id":"W4415941668","doi":"10.1016/j.annonc.2025.08.2237","title":"1609P Final, 9-year results from the CheckMate 238 phase III trial of adjuvant nivolumab vs ipilimumab in resected stage IIIB–C or IV melanoma","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Italfarmaco; Sun Pharma; Istituto Oncologico Veneto; Medizinische Universität Wien; Pfizer; Incyte; Odense Universitetshospital; Novo Nordisk; Astellas Pharma; Eisai; American Society of Clinical Oncology; Universität Wien; BeiGene; Regeneron Pharmaceuticals; Mylan; Helsinn; Les Laboratories Pierre Fabre; Society for Immunotherapy of Cancer; Daiichi Sankyo Europe; Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu; Hospices Civils de Lyon; Gilead Sciences; Univerzita Karlova v Praze; Melanoma Research Alliance; AstraZeneca; Associazione Italiana di Oncologia Medica; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; Sanofi; Johns Hopkins University; Melanoma Institute Australia; Amgen","keywords":"Ipilimumab; Nivolumab; Adjuvant; Melanoma; Stage (stratigraphy); Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001447935,0.000910809,0.001443035,0.0002585911,0.0004077812,0.001258819,0.0005764101,0.001211907,0.008475432],"category_scores_gemma":[0.001392139,0.0003475667,0.001893089,0.00024596,0.00038725,0.0007417108,0.0003398861,0.003049739,0.001625244],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009147252,"about_ca_system_score_gemma":0.0008404969,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001233632,"about_ca_topic_score_gemma":0.004752028,"domain_scores_codex":[0.9996895,0.0001378075,0.00001497455,0.00005494996,0.00004226682,0.00006045719],"domain_scores_gemma":[0.9993733,0.0001798667,0.00009464843,0.0000529735,0.0000563736,0.0002429525],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7895874,0.005590846,0.005054566,0.001298693,0.004854549,0.0003062108,0.0001078275,0.003073091,0.01496117,0.0005558541,0.06737129,0.1072384],"study_design_scores_gemma":[0.8150505,0.1112883,0.03413538,0.0002723623,0.004668215,0.0003716769,0.0001058859,0.002241071,0.003980445,0.001633694,0.02618389,0.00006859891],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9019701,0.01459031,0.001926559,0.008489291,0.003658747,0.002605611,0.03780753,0.0005013862,0.02845035],"genre_scores_gemma":[0.9092436,0.005355834,0.002624797,0.007471284,0.001236005,0.001790105,0.03833649,0.000221759,0.03372011],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008475432,"threshold_uncertainty_score":0.0283531,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1139519406823361,"score_gpt":0.4217627206791331,"score_spread":0.307810779996797,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}